Lonza names ceo of Life Science Ingredients Sector

Company: Lonza

Beat In-Albon brings relevant experience to the role

Beat In-Albon has joined Lonza as coo of the Life Science Ingredients Sector and has become a member of the Management Committee, replacing Harry Boot.

In-Albon brings broad industry experience to the new role, having worked for Lonza already from 1983–2006, where he was head of the Organic Fine & Performance Chemicals Division, and for SGS from 2006–2012, where he held different management positions.

In his new role In-Albon will focus primarily on the ‘Visp Challenge’ project, which is of significant importance to the expected profitability improvements in this sector.

‘I’m really happy to have Beat In-Albon back with Lonza. He brings on the one hand in-depth knowledge of the LSI business and the Visp site, and on the other hand valuable outside views,’ said Richard Ridinger, ceo of Lonza.

Boot will step down from the Management Committee and concentrate on his activities in Asia, especially in China.

You may also like

Ingredients

Staying ahead of the ADC curve

Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules
Manufacturing

Lonza to support development of ovarian cancer drug

The CDMO will provide kilogram-scale synthesis, purification, and stability testing for Oasmia’s drug candidate
Manufacturing

Lonza expands stem cell offering for humanised mouse models

Humanised mice are used to explore how novel cancer biotherapies interact with a human-specific immune system
Manufacturing

Lonza to supply prequalified cells for CN Bio OOC technology

Organ-on-a-chip technology has the potential to solve the issues presented by 2D cell cultures and animal models, the companies say
Ingredients

Lonza announces cryopreserved Leukopak offering

Fresh Leukopaks can be hard to access and must be used rapidly to avoid cell degradation, limiting transportation options
Ingredients

Lonza introduces hi-res HLA-typed primary cell lots

This offering builds on the company’s human primary cell capabilities
Ingredients

The Lonza powder-in-capsule microdosing approach

Jeff Williamson and Ben Sahacic explain how microdosing offers a proven approach for biopharmaceutical companies to quickly assess new drug candidates while minimising API consumption
Subscribe now